What to Expect at This Year’s Meeting

This year’s conference brings together a dozen leading experts on all things GU from across the country. Starting out the mornings lectures focused on prostate cancer, Leonard G. Gomella, MD, FACS, will update you on the latest in actionable biomarkers. Then, E. David Crawford, MD, will delve into the controversies surrounding PSA screening, reanalyzing clinical data and providing updated perspectives. Moving on, Daniel P. Petrylak, MD, will lead a panel discussion centered around challenging cases you’re likely to face in clinic. James B. Yu, MD, MHS, will review the current and future role of radiation therapy in prostate cancer, and then Robert Dreicer, MD, MS, MACP, FASCO, will delve into the latest advances in hormonal agents for your patients with prostate cancer.

Discussions will continue with Celestia S. Higano, MD, FACP, leading a discussion on the use of systemic therapy and Susan Slovin, MD, PhD, on the role of immunotherapy in prostate cancer.

After a guest lecture from our keynote speaker Ed Randall (more below), Maha H Hussain, MD, FACP, FASCO, will discuss the implications of nextgeneration sequencing and DNA damage repair pathways in prostate cancer. Wrapping up this portion of the conference, Dr. Gomella will lead another panel discussion featuring cases of patients with advanced disease.

After lunch, the conference will shift focus to cover renal cell carcinoma (RCC). First, David I Quinn, MBBS, PhD, FRACP, FACP, will provide an update on targeted therapies in RCC. Then, Mario Sznol, MD, will delve into the compelling advancements made in immunotherapy in recent years. David M Nanus, MD, will then discuss an updated strategic approach in the adjuvant and neoadjuvant settings before Dr. Petrylak again leads a case based panel, this time on the management of adverse events and treatment toxicities in your patients with RCC.

In the afternoon, New York GU™ will shift to the third GU malignancy of the program, urothelial carcinoma. Drs. Gomella and Petrylak will trade off through a series of lectures covering management strategies for bladder cancer, the immunotherapeutic breakthroughs in this disease, and concluding the conference with a final case-based debate.

Special attention will be made to variances in disease and care observed in prostate cancer at this year’s conference. Form biological underpinnings that predispose people to worsened disease, to important differences in availability of treatment, this is an important conversation to have.